Compare Iamgold Corporation Ordinary Shares (IAG) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iamgold Corporation Ordinary Shares vs Organon & Co. Common Stock — how do they compare? Iamgold Corporation Ordinary Shares trades at $17.22 (market cap $10.39B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: Iamgold Corporation Ordinary Shares is far larger — about 2.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Iamgold Corporation Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iamgold Corporation Ordinary Shares for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| IAG | OGN | |
|---|---|---|
Market Cap | $10.39B | $3.62B |
Volume | 2,784,290 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $24.57 | $13.81 |
52-Week Low | $10.96 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $10.43B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IAG trades at $18.27, down 1.62% today, with technical indicators showing a neutral bias. The company demonstrates strong fundamentals with a P/E of 9.23, net income margin of 31.4%, and ROE of 29.53%. Recent earnings show mixed results with two beats and one miss in the last three quarters. Analyst consensus is moderately bullish with a $22.00 price target, representing 20% upside potential from current levels.
IAG presents a compelling value opportunity with attractive valuation metrics and strong profitability. Key catalysts include Q3 2026 earnings release in November and operational optimization initiatives. Risks include commodity price volatility, execution challenges at mining operations, and potential cost pressures from rising fuel prices that could impact profitability.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Iamgold Corporation Ordinary Shares
IAMGOLD is a gold mining company with operations in Canada. It also explores and develops gold properties.
Read more on IAG →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
